Clinical Trials Browser

Phase 1/2 × Radiotherapy × 1 year × Clear all

NCT05099003 2026-05-27

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Phase 1/2 Recruiting

Glioma

NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1/2 Active not recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT02444741 2026-05-15

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1/2 Completed

124 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT04789486 2026-05-14

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03491683 2026-05-04

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

Glioblastoma

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT06477523 2026-04-29

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Phase 1/2 Active not recruiting

SCLC, Extensive Stage

NCT05765812 2026-04-28

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Phase 1/2 Recruiting

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Phase 1/2 Active not recruiting

Prostatic Diseases, Prostatic Neoplasms

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Phase 1/2 Recruiting

Glioma

NCT04454528 2026-03-10

BreastVAX

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

Advanced Bladder Cancer

NCT05491317 2026-02-19

A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

Phase 1/2 Terminated

Non-CNS Tumor

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03529448 2026-02-12

GEINOCANN

Phase 1/2 Completed

Glioblastoma

NCT01517451 2026-02-11

Radiation and Androgen Ablation for Prostate Cancer

Phase 1/2 Completed

45 enrolled 11 charts

Adenocarcinoma of the Prostate

NCT05039632 2026-02-06

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04599062 2026-01-29

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Phase 1/2 Active not recruiting

8 enrolled 8 charts

Sarcoma

NCT07312422 2026-01-26

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT00508443 2026-01-15

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalLymphoidSarcomaThoracic

Urogenital Diseases, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms, Sarcoma, Spinal Diseases, Spinal Neoplasms

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT02481635 2025-12-08

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03687957 2025-11-25

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Phase 1/2 Active not recruiting

42 enrolled 19 charts

Glioma

NCT04373785 2025-10-21

NG101m Adjuvant Therapy in Glioblastoma Patients

Phase 1/2 Not yet recruiting

Glioblastoma

NCT07196345 2025-09-29

TAS-102 Plus Radiotherapy in Elderly ESCC

Phase 1/2 Not yet recruiting

ESCC

NCT03174197 2025-09-24

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT03298893 2025-09-19

NiCOL

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT07177950 2025-09-17

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Phase 1/2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT05893654 2025-09-15

MELCOM

Phase 1/2 Enrolling by invitation

Uveal Melanoma, Melanoma

NCT03148327 2025-07-15

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04121455 2025-06-25

GLORIA

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT02730546 2025-06-22

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Phase 1/2 Completed

31 enrolled 20 charts

Gastrointestinal

Stomach Neoplasms

NCT04019262 2025-06-18

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Active not recruiting

Glioblastoma, Lymphopenia

NCT02655601 2025-06-08

BMX-HGG

Phase 1/2 Completed

177 enrolled 34 charts

Astrocytoma, Glioblastoma, Glioma

NCT03317327 2025-06-03

REPORT

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck